BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

PsychoGenics

PsychoGenics logo

Founded
1999
Patents
14

Technologies

AI Companies (Drug Discovery)

Neuropsychiatric disorders impact hundreds of millions of patients, many of whom have poor or no treatment options. Yet, despite the enormous human cost and societal burden, there have been almost no new mechanisms to treat major neuropsychiatric disorders in decades as the target-based approach of identifying highly selective targeted compounds has failed to deliver new and improved treatments for central nervous system (CNS) disorders. Instead, we rely on old drugs, some with serious side effects.

Become a Member to view additional information about this company